Company Overview
Reporting Period: Financial Year 2025-26
Document Dates: Multiple filings from May to July 2026
Financial Performance Highlights
Alkem Laboratories delivered strong financial results for FY 2025-26 with consolidated revenue growth of 13.5% to ₹14,712.3 crore and EBITDA growth of 19.6% to ₹3,005.2 crore. The company maintained a robust balance sheet with net cash of ₹5,474 crore and net debt-to-equity ratio of 0.10. Standalone performance showed revenue of ₹96,639.1 million with profit after tax of ₹22,820.9 million. The board recommended a final dividend of ₹10 per share, bringing total dividend for the year to ₹53 per share.
Strategic Initiatives & Expansion
MedTech Investment
The company executed a binding term sheet on 13th February 2026 to acquire 51-55% stake in Occlutech Holding AG at total equity value of €180.70 million (₹1,951.6 crore), entirely funded through internal accruals. This strategic move enters Alkem into the structural heart devices market with 200+ patents and presence in US, Western Europe, and Japan. Occlutech recorded €50 million net sales in CY2025 with 73% gross margins.
Business Transformation
Alkem transferred its Generic Business Undertaking to wholly-owned subsidiary Alkem Wellness Limited effective 1 October 2025 for ₹5,325.1 million on slump sale basis. The board also approved amalgamation of Adroit Biomed Limited with the company under Sections 230-232 of Companies Act, 2013.
Operational Performance
Domestic business grew 9.7% while international business expanded 22.5%, with 192 cumulative ANDA filings and 1,100+ product registrations globally. The company maintained 4.1% IPM share and ranked #3 in prescription generation, with 17 brands exceeding ₹100 crore in annual sales.
ESG & Sustainability Achievements
Alkem published its comprehensive Business Responsibility and Sustainability Report, demonstrating significant environmental progress including 15% reduction in Scope 1 & 2 emissions, 22% reduction in energy consumption, and 22.21 crore litres rainwater conservation. The company achieved 100% ISO 45001 certification coverage and spent ₹36.21 crore on CSR initiatives impacting 8.72 lakh beneficiaries. Gender diversity stood at 3.39% with target to reach 5% by FY27.
Corporate Governance & Leadership
Board Changes
Dr. Vikas Gupta resigned as Chief Executive Officer effective 30th June 2026. The board recommended reappointment of Mrs. Madhurima Singh as Executive Director for 5 years (2026-2031) and ratified appointment of Mr. Suresh D. Shenoy as Cost Auditor.
AGM Details
The 52nd Annual General Meeting is scheduled for 28th August 2026 through Video Conferencing/Other Audio-Visual Means. Key agenda items include dividend approval, director reappointments, and financial statement adoption. Remote e-voting is available from 24-26 August 2026.
Risk Management & Compliance
The company maintained comprehensive risk management policies covering credit, liquidity, and market risks. Foreign exchange exposure was hedged with USD 153 million forward contracts. Regulatory compliance remained strong with no material adverse remarks in secretarial audit report, though tax disputes totaling approximately ₹14,600 million remain under various appellate levels.
Outlook & Future Plans
Alkem plans to focus on chronic therapies expansion and new launches including GLP-1 portfolio in India, while entering 29 new international markets. MedTech expansion includes knee implants launch targeted for Q2 FY27 and hip implants for Q4 FY27. The company continues to target 42% reduction in Scope 1 & 2 emissions by FY2033 and water neutrality by FY2030.